Liabilities / Assets
74th percentile
Higher debt load relative to assets than 74% of similar nonprofits.
Primary Aldosteronism Foundation
990EZ • Fiscal year 2021 • EIN 84-3216292
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
0.06x
Liabilities / Revenue
74th percentile
Higher debt load relative to revenue than 74% of similar nonprofits.
Net Margin
94th percentile
Higher net margin than 94% of similar nonprofits.
Top Officer Pay
81st percentile
Higher top officer pay than 81% of similar nonprofits.
Top officer pay equals 17.9% of source-year revenue.
Asset Growth
Score unavailable
No earlier valid filing was available within the previous three public years.
Revenue Growth
Score unavailable
No earlier valid filing was available within the previous three public years.
Balance Sheet
Assets
$46,489
No earlier filing loaded for comparison.
Net Assets
$43,929
No earlier filing loaded for comparison.
Liabilities
$2,560
No earlier filing loaded for comparison.
Revenue And Expenses
Revenue
$57,322
No earlier filing loaded for comparison.
Expenses
$13,808
No earlier filing loaded for comparison.
Net Income
$43,514
No earlier filing loaded for comparison.
Historical Trend
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2021 to Dec 31, 2021
- Signed
- May 2, 2022
- Return Version
- 2021v4.0
- Gross Receipts
- $57,322
Mission and Program Overview
Mission
The primary aldosteronism foundation is committed to advancing standards of care for patients with hyperaldosteronism through proper diagnosis and treatment, actionable research, and inclusive collaboration.
The Primary Aldosteronism Foundation is committed to advancing standards of care for affected patients through proper diagnosis and treatment, actionable research and inclusive collaboration. To achieve its mission, the Foundation focuses on areas at the intersection of research, diagnosis, treatment and patient-oriented solutions.
Program Services
| Description | Grants | Expenses |
|---|---|---|
| Education on Primary Aldosteronism for Patients, Providers, and Stakeholders. The near absence of diagnosis and treatment of primary aldosteronism is in part due to a lack of education and the misconception that the disease is rare. The Foundation is addressing this area by: 1) Developing and maintaining an educational website on the disease with up-to-date information on diagnosis, treatment, research, and patient support with some 92 educational pages and 410 reference articles. 2) Supporting the development and maintenance of online directories of specialists and medical centers. 3) Building partnerships with relevant institutions and organizations (FH Foundation, T1D Exchange, National Kidney Foundation, AHA, CDC, NADF, WHL, Adrenal Alternatives). 4) Moderating two online support groups dedicated to primary aldosteronism. 5) Publishing educational fact sheets for patients and providers. 6) Using Twitter and other social media to promote awareness of the disease. 7) Collecting and editing stories from patients and publishing them to our website to inform others about the challenges of diagnosis and treatment. 8) Working with a group in Australia on the development of our first international charter as part of our worldwide mission. 9) Collecting and tracking signatures to our Open Letter in support of our efforts through our website. Other funding: In addition to cash donations, the Foundation received another $1,870 in in-kind service grants to host and maintain our website. | $0 | $4,661 |
| Primary Aldosteronism Roundtable and Summit. The Foundation has identified 11 factors across the healthcare sector that are responsible for the lack of diagnosis and treatment for PA. We've held consultations with the leadership of some 45 organization responsible for the factors, including: ASN, ACC, Endocrine Society, AAFP, ACP, AAES, SIRWEB, AHA, CDC, FDA, NIH, academic institutions, healthcare systems and payers, laboratories, pharmaceutical industries. Anticipated result: In June 2022, the Foundation will convene these stakeholders in a "Call to Action to Diagnose and Treat Primary Aldosteronism." Our goal is to establish a formal alliance coordinated by the Foundation to address these issues. Future outcomes: under the coordination of the Foundation, this groundwork will enable the design and implementation of programs for each of the 11 factors in order to remediate them. | $0 | $4,480 |
| Research and Innovation. Although discovered 60 years ago, the understanding of primary aldosteronism and its pathogenesis remains fragmented, and 95% of patients are neither diagnosed nor treated despite high disease prevalence (up to 13.5% of the population). 1) The Foundation has conducted an analysis of the disease's signs and symptoms, and of the critical factors contributing to lack of diagnosis and treatment. Outcome: identification of 11 factors across the healthcare sector; identification of over 50 signs and symptoms. 2) The Foundation has explored the ways in which implementation research can support the design and implementation of interventions needed to diagnose and treat primary aldosteronism in discussion with Johns Hopkins and University of WA at St Louis. 3) The Foundation is participating in the development of a predictive modeling tool leveraging artificial intelligence to identify affected patients and those at high risk for the disease in collaboration with Atomo and the University of Pennsylvania. 5) The Foundation is working with clinical researchers to advance the research agenda (University of Michigan, Harvard University, Mayo Clinic, NIH, Endocrine Society). Long-term goal: revision of current clinical guidelines; increase in research grants dedicated to primary aldosteronism. 6) The Foundation is working with industry leaders to translate advances into diagnostic and therapeutic solutions: Number of clinical trials supported: 5 (CinCor, Mineralys, PhaseBio, KBP Biosciences, FDA). Long-term goal: market availability of new FDA-approved drugs to treat primary aldosteronism. 7) The Foundation has co-authored an academic publication on primary aldosteronism. 8) The Foundation has compiled and is maintaining an online database of 454 academic articles published on primary aldosteronism. 9) The Foundation is participating as Associate Investigator on various multi-year grant applications. | $0 | $3,200 |
Compensation and Service Providers
Employees
| Name | Title | Full / Part Time | Base | Other | Total |
|---|---|---|---|---|---|
| Marianne Leenaerts | Director, Management Consultant | FT | $10,240 | - | $10,240 |
| Michael McGowan | Director, Principal Officer | PT | $0 | - | - |
| Rene Moreno | Director | PT | $0 | - | - |
| Deborah Kelly | Director | PT | $0 | - | - |
Governance and Compliance
Governance Explanations
Form 990-EZ, Part VI, Line 52
“The Primary Aldosteronism Foundation received an unusual grant of $50,000 in September 2021, payable in two tranches of $25,000 each. The first tranche was received in 2021. The second tranche will be received in 2022. The total amount of $50,000 was accrued in 2021.”
Filing and Contact Details
Filer
- Filer Name
- Primary Aldosteronism Foundation
- EIN
- 84-3216292
- Phone
- 6027260665
- Address
- 3533 E Ahwatukee CT, Phoenix, AZ 85044
Signing Officer
- Name
- Michael McGowan
- Title
- Principal Officer
- Phone
- 6024814123
- Signed
- 2022-05-02
Supplemental Narrative
Additional Explanations
Form 990-EZ, Part I, Line 8
“Incentive payment for using an online funds transfer service.”
Form 990-EZ, Part I, Line 16
“Description;Amount^Administrative expenses;629|Other program expenses;379^Total;1008^”
Form 990-EZ, Part II, Line 24
“Description;EOY Amount^Grants receivable;25000^Total;25000^”
Form 990-EZ, Part II, Line 26
“Description;EOY Amount^Contracts payable;2560^Total;2560^”
Raw XML Appendix200 raw XML fields
This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.
| Path | # | Value |
|---|---|---|
| IRS990EZ/ActivitiesNotPreviouslyRptInd | 0 | 0 |
| IRS990EZ/BenefitsPaidToOrForMembersAmt | 0 | 0 |
| IRS990EZ/BooksInCareOfDetail/PersonNm | 0 | Michael McGowan |
| IRS990EZ/BooksInCareOfDetail/PhoneNum | 0 | 6024814123 |
| IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt | 0 | 3533 E Ahwatukee CT |
| IRS990EZ/BooksInCareOfDetail/USAddress/CityNm | 0 | Phoenix |
| IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd | 0 | AZ |
| IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd | 0 | 85044 |
| IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt | 0 | 415 |
| IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt | 0 | 21489 |
| IRS990EZ/ChgMadeToOrgnzngDocNotRptInd | 0 | 0 |
| IRS990EZ/ContributionsGiftsGrantsEtcAmt | 0 | 57307 |
| IRS990EZ/CostOfGoodsSoldAmt | 0 | 0 |
| IRS990EZ/CostOrOtherBasisExpenseSaleAmt | 0 | 0 |
| IRS990EZ/DirectIndirectPltclExpendAmt | 0 | 0 |
| IRS990EZ/DonorAdvisedFndsInd | 0 | 0 |
| IRS990EZ/EngagedInExcessBenefitTransInd | 0 | 0 |
| IRS990EZ/ExcessOrDeficitForYearAmt | 0 | 43514 |
| IRS990EZ/FeesAndOtherPymtToIndCntrctAmt | 0 | 12800 |
| IRS990EZ/FiledScheduleAInd | 0 | 1 |
| IRS990EZ/ForeignFinancialAccountInd | 0 | 0 |
| IRS990EZ/ForeignOfficeInd | 0 | 0 |
| IRS990EZ/Form1120PolFiledInd | 0 | 0 |
| IRS990EZ/Form990TotalAssetsGrp/BOYAmt | 0 | 415 |
| IRS990EZ/Form990TotalAssetsGrp/EOYAmt | 0 | 46489 |
| IRS990EZ/FundraisingGrossIncomeAmt | 0 | 0 |
| IRS990EZ/GainOrLossFromSaleOfAssetsAmt | 0 | 0 |
| IRS990EZ/GamingGrossIncomeAmt | 0 | 0 |
| IRS990EZ/GrantsAndSimilarAmountsPaidAmt | 0 | 0 |
| IRS990EZ/GrossProfitLossSlsOfInvntryAmt | 0 | 0 |
| IRS990EZ/GrossReceiptsAmt | 0 | 57322 |
| IRS990EZ/GrossSalesOfInventoryAmt | 0 | 0 |
| IRS990EZ/InfoInScheduleOPartIIInd | 0 | X |
| IRS990EZ/InfoInScheduleOPartIInd | 0 | X |
| IRS990EZ/InfoInScheduleOPartVIInd | 0 | X |
| IRS990EZ/InvestmentIncomeAmt | 0 | 5 |
| IRS990EZ/LandAndBuildingsGrp/BOYAmt | 0 | 0 |
| IRS990EZ/LandAndBuildingsGrp/EOYAmt | 0 | 0 |
| IRS990EZ/LobbyingActivitiesInd | 0 | 0 |
| IRS990EZ/MadeLoansToFromOfficersInd | 0 | 0 |
| IRS990EZ/MembershipDuesAmt | 0 | 0 |
| IRS990EZ/MethodOfAccountingAccrualInd | 0 | X |
| IRS990EZ/NetAssetsOrFundBalancesBOYAmt | 0 | 415 |
| IRS990EZ/NetAssetsOrFundBalancesEOYAmt | 0 | 43929 |
| IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt | 0 | 415 |
| IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt | 0 | 43929 |
| IRS990EZ/OccupancyRentUtltsAndMaintAmt | 0 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 0 | 40 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 1 | 15 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 2 | 10 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 3 | 15 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 0 | 10240 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 1 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 2 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 3 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt | 0 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt | 1 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt | 2 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt | 3 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt | 0 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt | 1 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt | 2 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt | 3 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 0 | Marianne Leenaerts |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 1 | Michael McGowan |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 2 | Rene Moreno |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 3 | Deborah Kelly |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 0 | Director, Management Consultant |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 1 | Director, Principal Officer |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 2 | Director |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 3 | Director |
| IRS990EZ/OperateHospitalInd | 0 | 0 |
| IRS990EZ/Organization501c3Ind | 0 | X |
| IRS990EZ/OrganizationDissolvedEtcInd | 0 | 0 |
| IRS990EZ/OrganizationHadUBIInd | 0 | 0 |
| IRS990EZ/OtherAssetsTotalDetail/BOYAmt | 0 | 0 |
| IRS990EZ/OtherAssetsTotalDetail/EOYAmt | 0 | 25000 |
| IRS990EZ/OtherChangesInNetAssetsAmt | 0 | 0 |
| IRS990EZ/OtherExpensesTotalAmt | 0 | 1008 |
| IRS990EZ/OtherRevenueTotalAmt | 0 | 10 |
| IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt | 0 | NONE |
| IRS990EZ/PartVIOfCompOfHghstPdEmplTxt | 0 | NONE |
| IRS990EZ/PoliticalCampaignActyInd | 0 | 0 |
| IRS990EZ/PrimaryExemptPurposeTxt | 0 | The Primary Aldosteronism Foundation is committed to advancing standards of care for affected patients through proper diagnosis and treatment, actionable research and inclusive collaboration. To achieve its mission, the Foundation focuses on areas at the intersection of research, diagnosis, treatment and patient-oriented solutions. |
| IRS990EZ/PrintingPublicationsPostageAmt | 0 | 0 |
| IRS990EZ/ProgramServiceRevenueAmt | 0 | 0 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt | 0 | Primary Aldosteronism Roundtable and Summit. The Foundation has identified 11 factors across the healthcare sector that are responsible for the lack of diagnosis and treatment for PA. We've held consultations with the leadership of some 45 organization responsible for the factors, including: ASN, ACC, Endocrine Society, AAFP, ACP, AAES, SIRWEB, AHA, CDC, FDA, NIH, academic institutions, healthcare systems and payers, laboratories, pharmaceutical industries. Anticipated result: In June 2022, the Foundation will convene these stakeholders in a "Call to Action to Diagnose and Treat Primary Aldosteronism." Our goal is to establish a formal alliance coordinated by the Foundation to address these issues. Future outcomes: under the coordination of the Foundation, this groundwork will enable the design and implementation of programs for each of the 11 factors in order to remediate them. |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt | 1 | Research and Innovation. Although discovered 60 years ago, the understanding of primary aldosteronism and its pathogenesis remains fragmented, and 95% of patients are neither diagnosed nor treated despite high disease prevalence (up to 13.5% of the population). 1) The Foundation has conducted an analysis of the disease's signs and symptoms, and of the critical factors contributing to lack of diagnosis and treatment. Outcome: identification of 11 factors across the healthcare sector; identification of over 50 signs and symptoms. 2) The Foundation has explored the ways in which implementation research can support the design and implementation of interventions needed to diagnose and treat primary aldosteronism in discussion with Johns Hopkins and University of WA at St Louis. 3) The Foundation is participating in the development of a predictive modeling tool leveraging artificial intelligence to identify affected patients and those at high risk for the disease in collaboration with Atomo and the University of Pennsylvania. 5) The Foundation is working with clinical researchers to advance the research agenda (University of Michigan, Harvard University, Mayo Clinic, NIH, Endocrine Society). Long-term goal: revision of current clinical guidelines; increase in research grants dedicated to primary aldosteronism. 6) The Foundation is working with industry leaders to translate advances into diagnostic and therapeutic solutions: Number of clinical trials supported: 5 (CinCor, Mineralys, PhaseBio, KBP Biosciences, FDA). Long-term goal: market availability of new FDA-approved drugs to treat primary aldosteronism. 7) The Foundation has co-authored an academic publication on primary aldosteronism. 8) The Foundation has compiled and is maintaining an online database of 454 academic articles published on primary aldosteronism. 9) The Foundation is participating as Associate Investigator on various multi-year grant applications. |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt | 2 | Education on Primary Aldosteronism for Patients, Providers, and Stakeholders. The near absence of diagnosis and treatment of primary aldosteronism is in part due to a lack of education and the misconception that the disease is rare. The Foundation is addressing this area by: 1) Developing and maintaining an educational website on the disease with up-to-date information on diagnosis, treatment, research, and patient support with some 92 educational pages and 410 reference articles. 2) Supporting the development and maintenance of online directories of specialists and medical centers. 3) Building partnerships with relevant institutions and organizations (FH Foundation, T1D Exchange, National Kidney Foundation, AHA, CDC, NADF, WHL, Adrenal Alternatives). 4) Moderating two online support groups dedicated to primary aldosteronism. 5) Publishing educational fact sheets for patients and providers. 6) Using Twitter and other social media to promote awareness of the disease. 7) Collecting and editing stories from patients and publishing them to our website to inform others about the challenges of diagnosis and treatment. 8) Working with a group in Australia on the development of our first international charter as part of our worldwide mission. 9) Collecting and tracking signatures to our Open Letter in support of our efforts through our website. Other funding: In addition to cash donations, the Foundation received another $1,870 in in-kind service grants to host and maintain our website. |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt | 0 | 0 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt | 1 | 0 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt | 2 | 0 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt | 0 | 4480 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt | 1 | 3200 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt | 2 | 4661 |
| IRS990EZ/ProhibitedTaxShelterTransInd | 0 | 0 |
| IRS990EZ/RelatedOrganizationCtrlEntInd | 0 | 0 |
| IRS990EZ/SalariesOtherCompEmplBnftAmt | 0 | 0 |
| IRS990EZ/SaleOfAssetsGrossAmt | 0 | 0 |
| IRS990EZ/SchoolOperatingInd | 0 | 0 |
| IRS990EZ/SpecialEventsDirectExpensesAmt | 0 | 0 |
| IRS990EZ/SpecialEventsNetIncomeLossAmt | 0 | 0 |
| IRS990EZ/StatesWhereCopyOfReturnIsFldCd | 0 | AZ |
| IRS990EZ/SubjectToProxyTaxInd | 0 | 0 |
| IRS990EZ/SumOfTotalLiabilitiesGrp/BOYAmt | 0 | 0 |
| IRS990EZ/SumOfTotalLiabilitiesGrp/EOYAmt | 0 | 2560 |
| IRS990EZ/TanningServicesProvidedInd | 0 | 0 |
| IRS990EZ/TaxImposedOnOrganizationMgrAmt | 0 | 0 |
| IRS990EZ/TaxImposedUnderIRC4911Amt | 0 | 0 |
| IRS990EZ/TaxImposedUnderIRC4912Amt | 0 | 0 |
| IRS990EZ/TaxImposedUnderIRC4955Amt | 0 | 0 |
| IRS990EZ/TaxReimbursedByOrganizationAmt | 0 | 0 |
| IRS990EZ/TotalExpensesAmt | 0 | 13808 |
| IRS990EZ/TotalProgramServiceExpensesAmt | 0 | 12341 |
| IRS990EZ/TotalRevenueAmt | 0 | 57322 |
| IRS990EZ/TransactionWithControlEntInd | 0 | 0 |
| IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd | 0 | 0 |
| IRS990EZ/TypeOfOrganizationCorpInd | 0 | X |
| IRS990EZ/WebsiteAddressTxt | 0 | https://www.primaryaldosteronism.org |
| IRS990ScheduleA/First5Years170Ind | 0 | X |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt | 0 | 7307 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt | 0 | 400 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt | 0 | 1225 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt | 0 | 0 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus4YearsAmt | 0 | 0 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt | 0 | 8932 |
| IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/CurrentTaxYearMinus1YearAmt | 0 | 0 |
| IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/CurrentTaxYearMinus2YearsAmt | 0 | 0 |
| IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/CurrentTaxYearMinus3YearsAmt | 0 | 0 |
| IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/CurrentTaxYearMinus4YearsAmt | 0 | 0 |
| IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/TotalAmt | 0 | 0 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearAmt | 0 | 5 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus1YearAmt | 0 | 0 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus2YearsAmt | 0 | 0 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/TotalAmt | 0 | 5 |
| IRS990ScheduleA/GrossReceiptsRltdActivitiesAmt | 0 | 0 |
| IRS990ScheduleA/OtherIncome170Grp/CurrentTaxYearAmt | 0 | 0 |
| IRS990ScheduleA/OtherIncome170Grp/CurrentTaxYearMinus1YearAmt | 0 | 0 |
| IRS990ScheduleA/OtherIncome170Grp/CurrentTaxYearMinus2YearsAmt | 0 | 0 |
| IRS990ScheduleA/OtherIncome170Grp/TotalAmt | 0 | 0 |
| IRS990ScheduleA/PublicOrganization170Ind | 0 | X |
| IRS990ScheduleA/PublicSupportTotal170Amt | 0 | 2932 |
| IRS990ScheduleA/SubstantialContributorsTotAmt | 0 | 6000 |
| IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/CurrentTaxYearAmt | 0 | 0 |
| IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/CurrentTaxYearMinus1YearAmt | 0 | 0 |
| IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/CurrentTaxYearMinus2YearsAmt | 0 | 0 |
| IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/CurrentTaxYearMinus3YearsAmt | 0 | 0 |
| IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/CurrentTaxYearMinus4YearsAmt | 0 | 0 |
| IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/TotalAmt | 0 | 0 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt | 0 | 7307 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt | 0 | 400 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt | 0 | 1225 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt | 0 | 0 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt | 0 | 0 |
| IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt | 0 | 8932 |
| IRS990ScheduleA/TotalSupportAmt | 0 | 8947 |
| IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/CurrentTaxYearAmt | 0 | 10 |
| IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/CurrentTaxYearMinus1YearAmt | 0 | 0 |
| IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/CurrentTaxYearMinus2YearsAmt | 0 | 0 |
| IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/TotalAmt | 0 | 10 |
| IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine1 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorNum | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine1 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine2 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt | 0 | RESTRICTED |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 0 | Incentive payment for using an online funds transfer service. |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 1 | Description;Amount^Administrative expenses;629|Other program expenses;379^Total;1008^ |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 2 | Description;EOY Amount^Grants receivable;25000^Total;25000^ |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 3 | Description;EOY Amount^Contracts payable;2560^Total;2560^ |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 4 | The Primary Aldosteronism Foundation received an unusual grant of $50,000 in September 2021, payable in two tranches of $25,000 each. The first tranche was received in 2021. The second tranche will be received in 2022. The total amount of $50,000 was accrued in 2021. |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 0 | Form 990-EZ, Part I, Line 8 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 1 | Form 990-EZ, Part I, Line 16 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 2 | Form 990-EZ, Part II, Line 24 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 3 | Form 990-EZ, Part II, Line 26 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 4 | Form 990-EZ, Part VI, Line 52 |
| ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/AuthenticationAssuranceLevelCd | 0 | AAL2 |
| ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/LastSubmissionRqrOOBCd | 0 | 1 |
| ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/OOBSecurityVerificationCd | 0 | 11 |
| ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/TrustedCustomerCd | 0 | 0 |
| ReturnHeader/BuildTS | 0 | 2022-09-23 18:48:47Z |
| ReturnHeader/BusinessOfficerGrp/PersonNm | 0 | Michael McGowan |
| ReturnHeader/BusinessOfficerGrp/PersonTitleTxt | 0 | Principal Officer |
| ReturnHeader/BusinessOfficerGrp/PhoneNum | 0 | 6024814123 |
| ReturnHeader/BusinessOfficerGrp/SignatureDt | 0 | 2022-05-02 |
| ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt | 0 | PRIMARY ALDOSTERONISM FOUNDATION |
| ReturnHeader/Filer/BusinessNameControlTxt | 0 | PRIM |
| ReturnHeader/Filer/EIN | 0 | 843216292 |
| ReturnHeader/Filer/PhoneNum | 0 | 6027260665 |
| ReturnHeader/Filer/USAddress/AddressLine1Txt | 0 | 3533 E Ahwatukee CT |
| ReturnHeader/Filer/USAddress/CityNm | 0 | Phoenix |
| ReturnHeader/Filer/USAddress/StateAbbreviationCd | 0 | AZ |
| ReturnHeader/Filer/USAddress/ZIPCd | 0 | 85044 |
| ReturnHeader/ReturnTs | 0 | 2022-05-05T15:49:07-07:00 |
| ReturnHeader/ReturnTypeCd | 0 | 990EZ |
| ReturnHeader/TaxPeriodBeginDt | 0 | 2021-01-01 |
| ReturnHeader/TaxPeriodEndDt | 0 | 2021-12-31 |
| ReturnHeader/TaxYr | 0 | 2021 |
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2021 • Form 990EZDetailed filing. Detailed filing data is available for this year.
- Assets
- $46,489
- Liabilities
- $2,560
- Net assets
- $43,929
- Revenue
- $57,322
- Expenses
- $13,808
- Net income
- $43,514